{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:23:52Z","timestamp":1790871832018,"version":"4.1.0"},"reference-count":10,"publisher":"Centers for Disease Control MMWR Office","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7125e2","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T14:01:01Z","timestamp":1655820061000},"page":"830-833","source":"Crossref","is-referenced-by-count":70,"title":["Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment \u2014 California, December 2021\u2013May 2022"],"prefix":"10.15585","volume":"71","author":[{"given":"Deborah E.","family":"Malden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vennis","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno J.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley K.","family":"Ackerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lipsitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lewnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y.","family":"Tartof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19.","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R2","unstructured":"Food and Drug Administration. FDA updates on Paxlovid for health care providers. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. Accessed May 27, 2022. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-updates-paxlovid-health-care-providers"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R3","unstructured":"Gupta K, Strymish J, Stack G, Charness M. Rapid relapse of symptomatic omicron SARS CoV-2 infection following early suppression with nirmatrelvir\/ritonavir. Research Square [Preprint posted online April 6, 2022]. https:\/\/www.researchsquare.com\/article\/rs-1588371\/v1"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R4","unstructured":"Charness M, Gupta K, Stack G,  Rapid relapse of symptomatic omicron SARS-CoV-2 infection following early suppression with nirmatrelvir\/ritonavir. Research Square [Preprint posted May 12, 2022]. https:\/\/www.researchsquare.com\/article\/rs-1588371\/v2"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R5","unstructured":"Carlin AF, Clark AE, Chaillon A,  Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir\/ritonavir treatment. Research Square [Preprint posted May 18, 2022]. https:\/\/www.researchsquare.com\/article\/rs-1662783\/v1"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R6","unstructured":"CDC. CDC Health Advisory: COVID-19 rebound after Paxlovid treatment. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https:\/\/emergency.cdc.gov\/han\/2022\/pdf\/CDC_HAN_467.pdf"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R7","unstructured":"Food and Drug Administration. Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for Drug Evaluation and Research (CDER) review. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/155194\/download"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R9","unstructured":"Arbel R, Sagy YW, Hoshen M,  Oral nirmatrelvir and severe Covid-19 outcomes during the Omicron surge. Research Square [Preprint posted June 1, 2022]. https:\/\/www.researchsquare.com\/article\/rs-1705061\/v1"},{"key":"key-10.15585\/mmwr.mm7125e2-202206230936-R10","doi-asserted-by":"publisher","first-page":"ciac443","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high risk patients.","author":"Najjar-Debbiny","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T15:12:03Z","timestamp":1655997123000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7125e2.htm?s_cid=mm7125e2_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":10,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7125e2","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,24]]},"published":{"date-parts":[[2022,6,24]]}}}